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Abstract: Lactobacillus rhamnosus CRL1505 (Lr1505) stimulates immune responses in the gut and in the respiratory 
tract and improves resistance against Salmonella typhimurium and Streptococcus pneumoniae infections in 
immunocompetent and immunocompromised mice. Considering that respiratory infectious diseases continue to be a 
major cause of death among preschool children in developing countries, the aim of the present study was to evaluate the 
effect of Lr1505 on the health of children. A randomized-controlled double-blind clinical trial in 298 healthy children (2-5 
years old), attending daycare centers was performed. Yogurt containing Lr1505 was administered to children for 6 
months (five times a week). Results were statistically compared with those of children from the same community that 
received a placebo yogurt (without probiotic). Administration of Lr1505 to young children reduced the incidence of 
infections: 66% of children in the placebo group presented symptoms of infection while only 34% of cases were detected 
in the Lr1505 group. Significant differences (P<0.05) were detected in the incidence of intestinal infections, upper 
respiratory tract infections and angina when placebo and Lr1505 groups were compared. Children fed Lr1505 
experienced fewer fevers and needed fewer antibiotics than those receiving the placebo. The protective effect of Lr1505 
was associated with increased levels of mucosal IgA antibodies. Lr1505 is a promising resource for the development of 
prevention strategies against mucosal infections that could be effective tools for medical application. This new probiotic 
strain has been included into official Nutritional Programs in Argentina and it is given to more than 200 thousand 
children. This project has encouraged local milk production, thanks to the constant demand of probiotic yogurt containing 
L. rhamnosus CRL1505 by provincial governments, while incorporating innovation to small and medium enterprises. 
Keywords: Lactobacillus rhamnosus CRL1505, children, mucosal immunity, respiratory infections. 
1. INTRODUCTION 
Common infectious diseases continue to be a major 
cause of death among preschool children in developing 
countries [1-3]. The increase in antibiotic resistance 
and need for new and improved strategies to tackle 
infectious disease have led to an examination of the 
therapeutic potential of commensal induced modulation 
of the mucosal immune response. Consequently, it has 
been discovered that certain probiotic lactic acid  
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bacteria (LAB) do have protective effects against 
bacterial and viral infections in the gastrointestinal tract 
[4]. Significant attention has been focused on the role 
of probiotics in the protection of gut against pathogens. 
However, there is steadily increasing evidence that 
orally delivered probiotics are able to regulate immune 
responses outside the gastrointestinal tract, including 
the respiratory mucosa [5]. In mouse studies, it has 
been demonstrated that oral administration of probiotic 
LAB protects against respiratory pathogens such as 
Streptococcus pneumoniae [6, 7], Pseudomonas 
aeruginosa [8] and influenza virus [9]. Moreover, some 
human trials demonstrated that administration of 
probiotics has been associated with lower incidence of 
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ventilator-associated pneumonia [10], reduced 
respiratory infections in healthy and hospitalized 
children [11-13] and reduced duration of common cold 
infection [14]. 
With the aim to develop a new functional food able 
to improve both intestinal and respiratory immunity, we 
have evaluated the immunomodulatory capacity of 
several lactobacilli strains isolated from goat milk and 
we found that Lactobacillus rhamnosus CRL1505 
stimulates the innate and adaptive immune response in 
the gut in a dose-dependent way and confers 
resistance to infection with Salmonella typhimurium in 
immunocompetent [15] and immunocompromised 
malnourished [16] mice. Moreover, we have 
demonstrated that orally administered L. rhamnosus 
CRL1505 is able to increase the resistance to 
pneumococcal infection in immunocompetent mice and 
that this effect is associated with improvements of 
innate and adaptive immune responses in the 
respiratory tract [15]. In addition, we recently 
demonstrated that the use of L. rhamnosus CRL1505 
as a supplement in a repletion diet is able to improve 
the number and functionality of immune cells that 
participate in the response against a pneumococcal 
infection in malnourished mice [16]. 
Our studies in mice provided clear evidence that L. 
rhamnosus CRL1505 improves immune responses in 
the gut and beyond the gastrointestinal tract. However, 
the immunomodulatory effect of this strain was not 
tested in humans before. Therefore, in the present 
work we aimed to evaluate the effects of a probiotic 
yogurt containing the strain L. rhamnosus CRL1505 on 
the health of children attending pre-school daycare 
community centers. We evaluated the impact of 
probiotic yogurt containing L. rhamnosus CRL1505 on 
mucosal immunity and study its effect on the incidence 
and severity of gastrointestinal and respiratory 
infections. 
2. MATERIALS AND METHODS 
Study Design 
A randomised, double-blind, placebo-controlled 
study was conducted to evaluate the effect of the 
consumption of a probiotic yogurt on health of children. 
One children group was randomly allocated to the 
probiotic yogurt and the other to a placebo product. 
The study consisted of 6 months product consumption 
between July and December. The trial was conducted 
by nutritionists (SIPROSA), pediatricians (Tucuman 
Children Hospital), and immunologists (CERELA). In 
addition, daycare center staff was previously trained 
and allowed to participate. The experimental protocol 
and informed consent for parents were previously 
approved by the Ethics Committee of the Faculty of 
Medicine of the Tucuman University (Res. Nº 1121-06). 
Participants 
Healthy children attending daycare centers five-
days a week in Tucuman (Argentina) were recruited 
into the study. The purpose of the study was explained 
to the parents and a written informed consent was 
obtained. Procedure consisted of supervisor visiting the 
household and in presence of a third party, obtaining 
the consent from the mother or father after reading the 
consent form to them. 
Our inclusion criteria were: children between 2 and 
5 years old, from both sexes, adequate nutrition, 
attending daycares, who voluntarily agree to participate 
in the study, with written consent of parents or 
guardians. Before inclusion in the study, participants 
and the adults responsible for children were informed 
about the nature and characteristics of the study. Only 
those who met the eligibility criteria and whose parents 
or guardians gave their written consent to participate 
were included in the trial. 
Exclusion criteria were: congenital disease affecting 
the digestive system (cystic fibrosis, celiac disease, 
allergy to cow's milk), chronic diseases (pulmonary 
dysplasia, COPD, chronic renal failure). In addition, 
children or parents which do not accept participating in 
the study were not included. 
Intervention 
Children were randomised to receive either the 
probiotic yogurt or the placebo product. The probiotic 
yogurt was sweetened, flavoured, fermented milk 
containing at least 10
8
 colony-forming units (CFU)/100 
g of the probiotic strain Lactobacillus rhamnosus 
CRL1505 with a starter culture for yogurt prepared with 
Streptococcus thermophilus and Lactobacillus 
delbrueckii subsp. bulgaricus strains from the collection 
culture of CERELA. L. rhamnosus CRL1505, isolated 
from goat milk from northwestern Argentina, was 
previously selected by its ability to stimulate the 
immune system by increasing resistance to infection in 
the respiratory and intestinal tracts [15-17]. The 
placebo product was fermented milk produced with 
same starter culture without L. rhamnosus CRL1505. 
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The nutritional composition, appearance, taste and 
packaging of the probiotic yogurt and the placebo were 
identical throughout the study in order to maintain 
blinding. Enrolled children were randomly allocated to 
the two intervention groups and the participants were 
masked to group allocation. In addition, all the persons 
involved in the study, the different health professionals 
as well as the parents and guardians were unaware of 
the randomization codes. The secret codes were 
secured until completion of data entry for analysis. 
The Laboratory for Experimental Foods (CERELA-
CONICET) prepared the yogurt and probiotic cultures. 
The final products were elaborated by the dairy 
company “Al Pie de la Vaca” and were cold-stored 
(8ºC) in daycares. 
The probiotic yogurt and the placebo were 
administered daily from Monday to Friday (five days 
per week). During the study, children had to ingest one 
bottle of 100 g/day of yogurt or placebo product. 
Before initiation of the study, children underwent a 
clinical examination including anthropometric measures 
(weight, height). In addition, children and parents 
underwent a clinical nutrition questionnaire (which 
included personal data, medical history, family-
inherited diseases, psychomotor, environmental and 
sociocultural skills). 
The children were randomly allocated to probiotic 
yogurt or the placebo group on day zero of the study. 
Total of 298 children participated and were divided in 
two groups: 150 children were administered the 
probiotic yogurt while 148 children received the 
placebo. The clinical and nutritional monitoring was 
conducted by pediatricians from the Tucuman Children 
Hospital and by nutritionists from the SIPROSA 
Nutrition Division (Tucuman Government). 
During the study, visual controls of both placebo 
and probiotic yogurt consumption were performed by 
nutritionists. It was recorded that 100% of the products 
-probiotic yogurt and placebo- were consumed by the 
participants throughout the studied period.  
Assessment of Product Acceptability Using 
Hedonic Scale 
We assessed the quality of the product from the 
subjective point of view, considering that the success 
or failure of a food product depends not only on its 
composition or nutritional value, but also on subjective 
reactions associated with a pleasurable sensation. A 
hedonic test for children was used. The scale used was 
the hedonic faces with different facial expressions 
ranging from anger (complete dissatisfaction) to happy 
(complete satisfaction). Children expressed their 
opinion concerning a pleasant character on this scale. 
Yogurt and placebo products were coded so that 
recipients could not identify the product. The 
assessment of overall satisfaction was greater than 
90% in the strawberry- and vanilla-flavored yogurt. 
Follow Up Observation 
Planed visits were conducted once a week by 
pediatricians. In these visits, clinical examination of 
each child was performed as well as nutritional 
assessment (weight/age, height/age and weight/height 
ratios), according to the standards of the Provincial 
Health System of Tucumán (SIPROSA). 
In addition, during the trial the occurrence of 
infectious events related to the gastrointestinal and 
Table 1.  
Infection Main causative pathogen in children under 5 years Reference 
Acute otitis media Streptococcus pneumoniae and Haemophilus influenzae [18] 
Pharyngitis and tonsillitis Viral pathogens and -hemolytic streptococci  [19] 
Upper airway infections 
(common cold) 
Respiratory syncytial virus, Human metapneumovirus, Influenza A virus, 
Parainfluenza viruses and Rhinoviruses 
[20] 
Pneumonia Streptococcus pneumoniae, Haemophilus influenzae and Mycoplasma 
pneumoniae 
[21] 
Bronchitis Respiratory syncytial virus, Parainfluenza viruses and Rhinoviruses [22] 
Diarrhea Rotavirus and Adenovirus [23] 
Skin infections 
(impetigo and pyodermitis) 
Staphylococcus aureus and -hemolytic streptococci [24] 
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respiratory systems was recorded. Data collection was 
performed by a survey performed by paediatricians. 
The data were entered in individual forms for each child 
where the date and infectious characteristics were 
registered. The most common infectious diseases in 
children under five years were analysed: Acute otitis 
media, pharyngitis and tonsillitis, upper airway 
infections (common cold), pneumonia, bronchitis, 
diarrhoea and skin infections (impetigo and 
pyodermitis) (Table 1). 
Laboratory Tests 
Samples of faeces were collected at the beginning 
and end of the study in order to determine lactic acid 
bacteria counts. 
In addition, levels of IgA in saliva were determined. 
Samples were taken the day before the beginning of 
probiotic yogurt or placebo administration (Basal levels) 
and at the end of their administration (Post treatment 
levels). Saliva samples were collected from 200 
children (100 yogurt group and 100 in the placebo 
group) with sterile pasteur pipette and placed in 
appropriately labeled eppendorf tubes. Immediately 
after collection, the samples were cooled for transport 
to the laboratory. The samples were clarified by 
centrifugation at 2,500 g for 10 minutes, separated into 
aliquots and stored at -70 ° C until antibody 
assessment. Measurements were performed using the 
ELISA technique using anti-human IgA (Sigma # 
I0884). Total levels of antibody were quantified by 
linear regression analysis of the values of optical 
density (OD) of samples against a standard curve 
consisting of 10 serial dilutions of human IgA (Sigma # 
S5018). All the analytical dosages in the study were 
performed in blind. 
Data Analysis 
Statistics Division from CERELA was responsible 
for analysis of results. StatsDirect software was used. 
Appropriate parametric and non-parametric methods 
were employed according to the distribution of the data. 
The Student t test was used to compare means of the 
continuous variables with normal distribution. For 
variables with no normal distribution, the Mann-Whitney 
U test was used. The 2 test or Fisher exact test were 
used to compare percentages. The confidence interval 
of 95% was calculated using the same software. The 
difference between groups was considered significant 
for p <0.05. 
3. RESULTS 
Incidence of Infections 
As shown in Figure 1, there were 298 children 
enrolled in the study; 150 received the probiotic yogurt 
containing L. rhamnosus CRL1505 and 148 received 
the placebo product. There was no statistically 
significant difference between the groups in regard to 
age, gender, weight and height at the beginning of the 
study, or difference in weight and height prior to and 
after the intervention. Of the total of 298 children who 
participated, 132 (45%) of them presented infectious 
events during the trial (Figure 2A). The most common 
infectious diseases were upper respiratory infections 
followed by pharyngitis and tonsillitis, lower respiratory 
infections (acute bronchitis) and diarrhea (Figure 2A). 
In the group of children that recieved the yogurt 
containig the probiotic strain L. rhamnosus CRL1505 it 
was observed a significant decrease of infectious 
events when compared to the placebo group (34% vs 
66%) (Figure 2B). When the different types of 
infectious diseases were analyzed, we observed 
significant differences between the yogurt and placebo 
groups in the following events: upper respiratory 
infections (31% vs 69%), pharyngitis and tonsillitis 
(28% vs 72%) and acute diarrhea (26% vs 74%). No 
differences were observed in the incidence of 
bronchitis (Figure 2B). In addition, the number of 
children suffering pneumonia, otitis media or skin 
infections (impetigo and pyodermitis) did not allow us to 
perform statistical analysis (Figure 2B). Symptom 
duration of infection events for subjects in the placebo 
and the probiotic yogurt groups were not different 
(Figure 3A). The clinical effects of probiotic 
supplementation on the incidence of fever and the 
need of antibiotic tretament were also evaluated. 
Subjects in the probiotic yogurt group were found to 
have significantly lower incidence of having fever 
(Figure 3B). Furthermore, the need of antibiotic 
treatment among the probiotic-consuming children was 
significantly lower than that in the placebo group 
(Figure 3C). 
Lactic Acid Bacteria in Stools 
Analysis of the amount of LAB species in stools was 
performed after 6 months of product consumption. 
Comparison between groups was analysed by using a 
Mann–Whitney test. The results show no statistical 
difference between groups in the amount of LAB 
species in stools (P=0.6017; Figure 4). 
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Figure 1: Diagram showing the flow of participants through the stages of the study. 
 
 
Figure 2: Effects of a probiotic yogurt containing the strain Lactobacillus rhamnosus CRL1505 on the incidence of common 
infectious diseases in pre-school children. (A) Incidence of infections in the group of children, (B) different types of infectious 
diseases. (C, D) Effect of probiotic yogurt consumption in the incidence of infections. 
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Figure 3: Effects of a probiotic yogurt containing the strain Lactobacillus rhamnosus CRL1505 on the severity of common 
infectious diseases in pre-school children. (A) Symptom duration, (B) presence of fever, (C) use of antibiotics. 
 
Figure 4: Effects of a probiotic yogurt containing the strain 
Lactobacillus rhamnosus CRL1505 on faecal concentration of 
lactic acid bacteria in pre-school children. 
Levels of Immunoglobulin A in Saliva 
We performed the determination of IgA in saliva as 
a measure of mucosal immunity. Samples were taken 
the day before the begining of the intervention (basal 
levels) and at the end of probiotic or placebo 
administration (post-treatment levels). No significant 
differences were observed in the basal levels of IgA 
when the probiotic yogurt and the placebo were 
compared (Figure 5). On the contrary, we observed a 
significant increase in IgA levels in children who 
received the probiotic yogurt while the post-treatment 
levels of IgA in the placebo group were similar to those 
found at the beginning of the trial (Figure 5). Therefore, 
the consumption of probiotic containing L. rhamnosus 
CRL1505 strain is able to improve mucosal immunity 
as reveled by the levels of IgA in saliva. 
4. DISCUSSION 
Reducing the preventable childhood illnesses 
among preschool children in developing countries is an 
important public health goal, that would not only impact 
mortality but would also impact better development of 
children. It has been estimated that 5.2 million children 
under five years of age die every year due to 
preventable infectious diseases like pneumonia and 
diarrhea [1]. Moreover, recent findings suggest 21% of 
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global deaths in children younger than 5 years of age 
are attributable to malnutrition and its synergistic 
relationship with preventable infectious diseases [2, 3]. 
Our region is no exception to these global statistics. 
Fortification with probiotics may provide one of the 
potential interventions to reduce the burden of common 
childhood morbidities [25]. Data on the use of 
probiotics in preventing common childhood illnesses in 
a community setting from developing countries is 
lacking as are data evaluating the effect on illness 
other than diarrhea. In this study, we report the first 
randomized controlled trial, evaluating the effect of a 
probiotic yogurt on both gut and non-gut related 
illnesses among children from Tucuman, Argentina. 
Children in probiotic yogurt and placebo groups 
consumed similar amounts of yogurt, and yogurt in 
both groups was isoenergic, with identical 
macronutrient quality and quantity as well as quantity of 
vitamins and minerals. The only difference was that the 
yogurt for children allocated to the probiotic group 
delivered additionally 10
8
 CFU/day of the probiotic 
strain L. rhamnosus CRL1505. 
We demonstrated that administration of L. 
rhamnosus CRL1505 improved mucosal immunity and 
reduced the incidence and severity of intestinal and 
respiratory infection in children. When we studied the 
type of infectious events according to their location and 
symptoms, the frequency of them was consistent with 
the prevalence reported in our country. The most 
common infectious diseases were upper respiratory 
infections, followed by angina and then lower 
respiratory infections (acute bronchitis) and diarrhea 
[18, 21, 22, 23]. We registered that 34% of children 
who consumed the probiotic yogurt showed some type 
of infectious event, while in the placebo group this 
value was higher reaching a 66% of children. These 
results demonstrate a significant reduction in 
occurrence of infectious events associated with 
consumption of L. rhamnosus CRL1505. We also 
evaluated the presence or absence of fever during 
infectious events as well as the need of antibiotic 
treatment in children who had infections, as indicators 
of severity. There was a significant decrease in the 
presence of fever in children who consumed probiotic 
yogurt as well as a slight decrease in the need for 
antibiotic treatment, indicating less serious infections in 
relation to the placebo group. 
Several studies have demonstrated that probiotics 
are able to improve intestinal immunity and reduce 
susceptibility to intestinal pathogens in children. For 
example, a study of young children afflicted with 
rotavirus gastroenteritis showed that L. reuteri 
significantly shortened the duration of diarrhea [26]. 
Another clinical trail demonstrated that children with 
mild diarrhea who consumed the combination of L. 
rhamnosus and L. reuteri experienced a reduction in 
the duration of the diarrhea [27]. More recently, a meta-
analysis performed by Salari et al., [28] showed that 
probiotics administration significantly decreased the 
duration of diarrhea and fever in children. These 
studies illustrated the beneficial effects of different 
lactobacilli on gastrointestinal infections and they are in 
accordance with our results. On the contrary, few 
studies have evaluated whether probiotics are capable 
of preventing respiratory infections and reducing their 
severity in children. Some studies have examined the 
role of probiotics in the prevention of respiratory tract 
infections in healthy individuals [29, 30]; particularly 
those in children’s daycare centers [11, 31]. Results 
from a study evaluating Bifidobacterium lactis or 
Lactobacillus reuteri versus placebo did not show a 
beneficial probiotic effect on the rate and duration of 
respiratory illnesses [31]. On the other hand, 
randomized, double- blind, placebo-controlled studies 
performed in daycare centers showed that 
administration of Lactobacillus GG resulted in a 
reduction in the number of children suffering from 
respiratory tract infections [11, 13]. Moreover, 
treatment with Lactobacillus GG significantly reduces 
the risk for developing nosocomial respiratory tract 
infections in children who were hospitalized on a 
 
Figure 5: Effects of a probiotic yogurt containing the strain 
Lactobacillus rhamnosus CRL1505 on saliva IgA levels in 
pre-school children. (A) basal levels at the beginning of the 
trial, (B) levels of IgA after six month of treatment. * 
Significant differences when compared with the placebo 
group (P < 0.05). 
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pediatric ward [12]. These results suggest that not all 
the probiotic strains that are able to stimulate intestinal 
defenses are capable to improve respiratory immunity. 
Therefore, certain LAB strains may share certain 
functional properties. However, some of them can 
perform a functional role better than others, so it is 
important to carry out thorough studies on specific 
strains, according to their therapeutic use. In this 
sense, our systematic studies in animals on the ability 
of LAB strains to improve respiratory immunity, allowed 
us to select a strain that is likely to have a beneficial 
effect in humans, which has been demonstrated in this 
clinical trial. 
The study of the mechanisms responsible for the 
beneficial role of probiotics on the gut have 
documented direct anti-microbial effects and 
improvement in mucosal barrier function as a result of 
the effects of probiotics on both innate and adaptive 
immunity. However, the mechanisms responsible for 
the improvement of defenses against upper respiratory 
infections have not been fully elucidated. We have 
made some progress in the knowledge of the 
immunological mechanisms involved in the protective 
effect of L. rhamnosus CRL1505 against respiratory 
pathogens [32]. 
Our laboratory has demonstrated that the oral 
administration of certain LAB strains is able to induce 
the IgA cycle and increase the IgA
+
 cell population in 
the respiratory tract [7, 33]. In the case of L. rhamnosus 
CRL1505 we found that this strain was capable of 
increasing the number of IgA
+
 cells in intestine and 
bronchus of mice [15]. We also found that L. 
rhamnosus CRL1505 was able to improve the 
production of anti-pneumococcal IgA in the airways 
[15]. The production of IgA in the respiratory tract 
during an infectious process is important because it 
prevents colonization of mucosal tissues and 
subsequent spreading into the systemic circulation [34]. 
Additionally, IgA antibodies can bind antigens and 
minimize their entry with a consequent reduction in 
inflammatory reactions, which prevents potentially 
harmful effects on the tissue. In this study we found 
improved levels of IgA in children that received the 
probiotic, therefore we assume that the stimulation of 
the IgA cycle and the improvement of the levels of IgA 
induced by the L. rhamnosus CRL1505 could partly 
explain the greater resistance of children to respiratory 
infections. 
On the other hand, it is known that the symptoms 
associated with common cold are a result of the 
inflammatory response by the host towards the 
infection. Therefore, compounds with the capacity to 
improve immunity and control unproductive 
inflammation are supposed to be effective antivirals. In 
this sense, we have demonstrated in animal studies 
that treatments with L. rhamnosus CRL1505 prior to 
pneumococcal infection induced a significant increase 
in IL-10 in lung and serum [15]. Consequently, in 
agreement with other reports [35], IL-10 was valuable 
to attenuate inflammatory damage and 
pathophysiological alterations in lung infected with 
pneumococci. According to our results, L. rhamnosus 
CRL1505 treatment would beneficially regulate the 
balance between pro- and anti-inflammatory cytokines, 
allowing a more effective inflammatory response 
against infection. This controlled inflammatory 
response induced by L. rhamnosus CRL1505 could 
explain the beneficial effect of this strain in the 
incidence and severity of common cold observed in our 
study. 
Although we did not evaluate etiology of diarrhea in 
this study, previous evaluations have shown rotavirus 
and adenovirus to be responsible for most cases of 
intestinal infection in children [23]. In addition, viral 
pathogens, such as respiratory syncytial virus, human 
metapneumovirus, influenza A virus, parainfluenza 
viruses, and rhinoviruses are considered the major 
viruses that can cause respiratory tract diseases in 
children [20]. Therefore, the findings of this study 
suggest that administration of L. rhamnosus CRL1505 
may provide one of the potential interventions to 
reduce the burden of common childhood morbidities, 
especially those associated to viral infections. The 
precise cellular and molecular mechanisms involved in 
the improvement of antiviral immunity induced by L. 
rhamnosus CRL1505 is an interesting topic for future 
investigations. 
In this work, we demonstrated that consumption of a 
fermented dairy product containing L. rhamnosus 
CRL1505 is associated with a significant decrease in 
the duration and severity of mucosal infections 
providing the first evidence that a dairy fermented 
product containing this immunobiotic strain may have a 
beneficial effect against respiratory infections in young 
children. Based on the results summarized in this work 
and given the high morbidity and mortality in children 
especially associated with airways infectious diseases, 
dietary intervention using a dairy product containing the 
probiotic strain L. rhamnosus CRL1505 can be useful 
to improve health status of this vulnerable population. 
From the above, this new probiotic strain has been 
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included into official National Nutritional Programs in 
Argentina. Since 2008, the probiotic yogurt containing 
L. rhamnosus CRL1505 (YOGURITO
®
) is given daily to 
more than 200 thousand children in Tucumán city 
thanks to the Government actions (Social Development 
Ministry). The use of the immunobiotic CRL1505 strain 
to improve children health has already transcended the 
limits of Tucuman province since other provinces in 
Argentina are also participating in this Social Program 
and more children are being benefited with the 
probiotic YOGURITO
®
. 
The social project YOGURITO
® 
has multiple positive 
impacts at different levels, in the regional economy by 
encouraging both the local milk production and the 
competitiveness in small and medium enterprises 
(SMEs) through innovation and dairy products 
differentiation; in the children education and health 
status by improving wellness and the immune system 
from the basis that “more health is equal to less school 
desertion”. 
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